Skip to main content

Chronic Lymphocytic Leukemia

Featured Article
By preemptively looking for patients with chronic lymphocytic leukemia (CLL) who are most likely to not respond to therapy with Bruton's tyrosine kinase (BTK) inhibitors in the long-term, or who will…
Treatment consisting of CD19-specific chimeric antigen receptor (CAR) T-cell therapy and concurrent ibrutinib demonstrated improved outcomes and fewer severe adverse events in patients with relapsed…
Back to Top